Tan Li
Founder at SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Net worth: 487 M $ as of 2024-06-29
Profile
Tan Li founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Ms. Li is Executive Director & Deputy General Manager at this company and Executive Partner at Urumqi Jintiantu Equity Investment Partnership LP. Ms. Li is also on the board of Kymab Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. and Kymab Group Ltd. She received an undergraduate degree from Sichuan University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-06-29 | 408,041,280 ( 32.72% ) | 487 M $ | 2024-06-29 |
Tan Li active positions
Companies | Position | Start |
---|---|---|
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Founder | 1998-04-20 |
Urumqi Jintiantu Equity Investment Partnership LP | Corporate Officer/Principal | 2013-08-08 |
Shenzhen Techdow Pharmaceutical Co., Ltd. | Director/Board Member | - |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Director/Board Member | 2014-01-12 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 2017-01-19 |
Training of Tan Li
Sichuan University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Health Technology |
Private companies | 5 |
---|---|
Urumqi Jintiantu Equity Investment Partnership LP | |
Shenzhen Techdow Pharmaceutical Co., Ltd. | |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Distribution Services |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
- Stock Market
- Insiders
- Tan Li